Comparative study of prophylactic oral ganciclovir and valacyclovir in high-risk kidney transplant recipients

Nephrology Dialysis Transplantation

Volumn 18, Issue 4, 2003, Pages 809-813

  Yango, Angelito ^a   Morrissey, Paul ^a   Zanabli, Abdurahman ^a   Beaulieu, James ^a   Shemin, Douglas ^a   Dworkin, Lance ^a   Monaco, Anthony ^a   Gohh, Reginald ^a  

^a RHODE ISLAND HOSPITAL   (United States)

Author keywords

Cytomegalovirus; Ganciclovir; Kidney transplantation; Prophylaxis; Treatment; Valacyclovir

Indexed keywords

ACICLOVIR; CALCINEURIN; CLOTRIMAZOLE; COTRIMOXAZOLE; CYCLOSPORIN; GANCICLOVIR; KETOCONAZOLE; LYMPHOCYTE ANTIBODY; MONOCLONAL ANTIBODY; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PENTAMIDINE; POLYCLONAL ANTIBODY; PREDNISONE; PRODRUG; TACROLIMUS; VALACICLOVIR;

ADULT; AREA UNDER THE CURVE; ARTICLE; CHEMOPROPHYLAXIS; COMPARATIVE STUDY; CONTROLLED STUDY; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG EFFICACY; DRUG HALF LIFE; FEMALE; FOLLOW UP; HIGH RISK PATIENT; HUMAN; INCIDENCE; KIDNEY DONOR; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MORTALITY; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; RECIPIENT; RETROSPECTIVE STUDY;

ACYCLOVIR; ADMINISTRATION, ORAL; ADULT; CYTOMEGALOVIRUS INFECTIONS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; GANCICLOVIR; GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; KIDNEY FAILURE, CHRONIC; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; OPPORTUNISTIC INFECTIONS; PREOPERATIVE CARE; PROBABILITY; RETROSPECTIVE STUDIES; RISK ASSESSMENT; TREATMENT OUTCOME; VALINE;

EID: 0037383846     PISSN: 09310509     EISSN: None     Source Type: Journal    
DOI: 10.1093/ndt/gfg039     Document Type: Article

References (20)

1. Farrugia E, Schwab TR. Management and prevention of cytomegalovirus infection after renal transplantation. Mayo Clinic Proc 1992; 67: 879-890
2. Hokeberg I, Erikson BM, Zweygberg-Wirtgart B, Tufresson G, Olding-Stenkvist E, Griller L. Diagnostic markers and risk factors for cytomegalovirus infection and disease in renal allograft recipients. Scand J Infect Dis 1995; 27: 435-440
3. Tolkoff-Rubin N, Rubin R. Recent advances in diagnosis and management of infection in the organ transplant recipient. Semin Nephrol 2000; 20: 148-163
4. Pouteil-Noble C, Ecochard R, Landrivon G et al. Cytomegalovirus infection - an etiological factor for rejection? A prospective study in 242 renal transplant patients. Transplantation 1993; 55: 851-857
5. Flechner S, Avery R, Fisher R et al. A randomized prospective controlled trial of oral acyclovir versus oral ganciclovir for cytomegalovirus prophylaxis in high-risk kidney transplant recipients. Transplantation 1998; 66: 1682-1688
6. Kletzmayr K, Kreuzwieser E, Watkins-Riedel T, Berlakovich G, Kovarik J, Klauser R. Long-term oral ganciclovir prophylaxis for prevention of cytomegalovirus infection and disease in cytomegalovirus high risk transplant recipients. Transplantation 2000; 70: 1174-1180
7. Lowance D, Neumayer H, Legendre CM et al. Valacyclovir for the prevention of cytomegalovirus disease after renal transplantation. N Engl J Med 1999; 340: 1462-1470
8. Sagedal S, Nordal K, Hartman A et al. A prospective study of the natural course of cytomegalovirus infection and disease in renal allograft recipients. Transplantation 2000; 70: 1166-1174
9. Hibberd PL, Tolkoff-Rubin NE, Cosimi AB et al. Symptomatic cytomegalovirus disease in the cytomegalovirus antibody seropositive renal transplant recipient treated with OKT3. Transplantation 1992; 53: 68-72
10. Kutzmayr J, Kotzmann H, Popow-Kraupp T, Kovarik J, Klauser R. Impact of high dose oral acyclovir prophylaxis on cytomegalovirus disease in CMV high risk renal transplant recipients. J Am Soc Nephrol 1996; 7: 325-330
11. Fletcher CV, Englund JA, Edelman CK, Gross CR, Dunn DL, Balfour HH. Pharmacologic basis of high-dose oral acyclovir prophylaxis of cytomegalovirus disease in renal allograft recipients. Antimicrob Agents Chemother 1991; 35: 938-943
12. Brennan D, Garlock K, Singer G et al. Prophylactic oral gancyclovir compared with deferred treatment for control of cytomegalovirus in renal transplant recipients. Transplantation 1997; 64: 1843-1846
13. Weller S, Blum MR, Doucette M et al. Pharmacokinetics of the acyclovir pro-drug valacyclovir after escalating single- and multiple-dose administration to normal volunteers. Clin Pharmacol Ther 1993; 54: 595-605
14. Couchoud C, Cucherat M, Haugh M, Pouteil-Noble C. Cytomegalovirus prophylaxis with antiviral agents in solid organ transplantation: a meta-analysis. Transplantation 1998; 65: 641-647
15. Sawyer MH, Webb DE, Balow JE, Strauss SE. Acyclovir-induced renal failure: clinical course and histology. Am J Med 1988; 84: 1067-1071
16. Baldanti F, Simoncini L, Sarasini A et al. Gancyclovir resistance as a result of oral gancyclovir in a heart transplant recipient with multiple human cytomegalovirus strains in blood. Transplantation 1998; 66: 324-329
17. Aitken C, Barret-Muir W, Raferty M, Breur J. The clinical significance of gancyclovir resistance in a renal transplant patient. Nephrol Dial Transplant 1999; 14: 1050-1051
18. Gnann JW, Barton NH, Whitley RJ. Acyclovir: mechanism of action, pharmakokinetics, safety and clinical applications. Pharmacotherapy 1983; 3: 275-283
19. Laskin OL. Clinical pharmacokinetics of acyclovir. Clin Pharmacokinet 1983; 8: 187-201
20. Wagstaff AJ, Faulds D, Goa KL. Acyclovir: a reappraisal of its antiviral activity, pharmacokinetic properties and therapeutic efficacy. Drugs 1994; 47: 153-205